Market revenue in 2022 | USD 160.3 million |
Market revenue in 2030 | USD 375.9 million |
Growth rate | 11.2% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 51.59% in 2022. Horizon Databook has segmented the Japan non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
Japan's National Health Insurance System reimburses almost all locally available molecular diagnostics products. It is not legal in Japan to purchase devices that the government has not approved for reimbursement. Some devices are reimbursed based on product category, while others are reimbursed through procedure fees.
The reimbursement rate for devices is revised every 2 years. In Japan, reimbursement usually takes 9 months post product approval. However, if manufacturers try to categorize a product into a higher reimbursement class or increase reimbursement, the procedure can take more than 1 year.
The Japan Health Insurance Association (JHIA) and other health insurance providers cover certain workers. JHIA receives contributions from insured persons, employees, and the government. Universal health coverage is a distinctive feature of the country's healthcare system.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into Japan non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account